PHARMACEUTICAL COMBINATION OF MEK INHIBITOR AND B-RAF INHIBITORS
A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. melanoma.
1 . A combination comprising:
(i) a compound of formula (I)
or solvate thereof; and
(ii) a compound of formula (II)
or a pharmaceutically acceptable salt thereof.
2 . A combination according to claim 1 wherein compound (i) is in the form of the dimethylsulfoxide solvate and the compound (ii) is in the form of the methanesulfonate salt.
3 . A combination kit comprising a combination according claim 1 together with a pharmaceutically acceptable carrier or carriers.
4 . A pharmaceutical composition comprising a combination according to claim 1 together with a pharmaceutically acceptable diluent or carrier.
5 . A method of treating melanoma in a human in need thereof which comprises the administration of a therapeutically effective amount of
(i) a compound of formula (I)
or solvate thereof; and
(ii) a compound of formula (II)
or a pharmaceutically acceptable salt thereof.
6 . The method of claim 5 , wherein compound (i) is in the form of the dimethylsulfoxide solvate.
7 . The method of claim 5 , wherein the compound (ii) is in the form of the methanesulfonate salt.
8 . The method of claim 5 , wherein the melanoma is metastatic melanoma.
9 . The method of claim 5 , wherein the melanoma is BRAFV600E mutant melanoma.